Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022

Stoliaroff-Pépin, Anna; Peine, Michael; Herath, Tim; Lachmann, Johannes; Perriat, Delphine; Dörre, Achim; Nitsche, Andreas; Michel, Janine; Grossegesse, Marica; Hofmann, Natalie; Rinner, Thomas; Kohl, Claudia; Brinkmann, Annika; Meyer, Tanja; Dorner, Brigitte G.; Stern, Daniel; Treindl, Fridolin; Hein, Sascha; Werel, Laura; Hildt, Eberhard; Gläser, Sven; Schühlen, Helmut; Isner, Caroline; Peric, Alexander; Ghouzi, Ammar; Reichardt, Annette; Janneck, Matthias; Lock, Guntram; Schaade, Lars; Wichmann, Ole; Harder, Thomas

doi:10.1016/j.vaccine.2022.11.065

Cited by 7 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The proportion of older patients and cases with immunocompromising comorbidities in the Omicron wave was higher compared with our data from an earlier recruitment phase in the Delta wave [9]. This difference in clinical characteristics was confirmed in other studies [18,19].…”

Section: Discussionsupporting

confidence: 89%

“…The proportion of unvaccinated cases and controls was markedly lower in the Omicron wave compared to the Delta wave [9] and the percentage of boostered cases and controls increased. The increase might be related to the awareness campaign for vaccination in Germany and to increasing confidence in the vaccines.…”

Section: Discussionmentioning

confidence: 99%

“…Patients with comorbidities often have a fragile health situation, and even a mild or moderate SARS-CoV-2 infection can impair the state of health and lead to hospital admission with COVID-19 as the main diagnosis. However, the lower pathogenicity of the Omicron variant and the advanced therapeutical possibilities still led to milder disease in the Omicron wave compared with the Delta wave [9,[18][19][20].…”

Section: Discussionmentioning

confidence: 99%

“…In addition, we performed subgroup analyses and studied different time intervals of protection. Initial data collected during the Delta wave were published recently [9]. Here we present the profile of hospitalized COVIK-19-patients and COVID-19 VE based on data obtained during the Omicron wave.…”

Section: Introductionmentioning

confidence: 99%

“…Vaccine effectiveness (VE) against the wild-type virus and the Alpha, Beta and Delta variants was very high irrespective of outcome definition [9, 10]. Previous studies showed decreased VE against the Omicron variant due to mutations in the spike protein, but effectiveness against severe disease remained high [11, 12].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: Results from the COViK study

Stoliaroff

Peine

Herath

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Purpose: COViK - a prospective hospital-based multicenter case-control study in Germany - aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave. Methods: We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates. Results: 21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12-78%), 81.5% (95% CI: 68-90%) and 95.6% (95% CI: 88-99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses. Conclusion: Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: Results from the COViK study

Stoliaroff

Peine

Herath

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study

et al. 2023

View full text Add to dashboard Cite

Purpose COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave. Methods We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates. Results 21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12–78%), 81.5% (95% CI: 68–90%) and 95.6% (95%CI: 88–99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses. Conclusion Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.

show abstract

Direct comparison of clinical diagnostic sensitivity of saliva from buccal swabs versus combined oro-/nasopharyngeal swabs in the detection of SARS-CoV-2 B.1.1.529 Omicron

Puyskens

Michel

Stoliaroff-Pépin

et al. 2023

Journal of Clinical Virology

Self Cite

View full text Add to dashboard Cite

Effectiveness of vaccines in preventing hospitalization due to COVID-19: A multicenter hospital-based case-control study, Germany, June 2021 to January 2022

Cited by 7 publications

References 8 publications

Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: Results from the COViK study

Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: Results from the COViK study

Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: results from the COViK study

Direct comparison of clinical diagnostic sensitivity of saliva from buccal swabs versus combined oro-/nasopharyngeal swabs in the detection of SARS-CoV-2 B.1.1.529 Omicron

Contact Info

Product

Resources

About